Development of SARS-CoV-2 entry antivirals
Open Access
- 30 January 2024
- journal article
- review article
- Published by Elsevier in Cell Insight
- Vol. 3 (1) , 100144
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82274204)
- Natural Science Foundation of Shandong Province (2021GXRC028, ZR2021ZD17)
This publication has 98 references indexed in Scilit:
- Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)Journal of Biological Chemistry, 2016
- Design of a Potent Antibiotic Peptide Based on the Active Region of Human Defensin 5Journal of Medicinal Chemistry, 2015
- Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus EntryJournal of Virology, 2012
- Aprotinin and similar protease inhibitors as drugs against influenzaAntiviral Research, 2011
- Characterization of a Highly Conserved Domain within the Severe Acute Respiratory Syndrome Coronavirus Spike Protein S2 Domain with Characteristics of a Viral Fusion PeptideJournal of Virology, 2009
- Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sitesProceedings of the National Academy of Sciences, 2009
- Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interactionAntiviral Research, 2007
- Paneth cell antimicrobial peptides: Topographical distribution and quantification in human gastrointestinal tissuesFEBS Letters, 2006
- Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entryProceedings of the National Academy of Sciences, 2005
- Protection of mice by a protease inhibitor, aprotinin, against lethal Sendai virus pneumoniaJournal of General Virology, 1991